EVALUATION OF MARKETED KITS FOR MEASUREMENT OF ABP 501, THE FIRST APPROVED ADALIMUMAB BIOSIMILAR, DRUG CONCENTRATION AND ANTI-DRUG ANTIBODY LEVELS IN PATIENT SERUM

被引：0
|
作者：
Mytych, Dan [1 ]
Manning, Marta Starcevic [1 ]
Colbert, Alexander [1 ]
Hoofring, Sarah [1 ]
Miller, Jill [1 ]
Gessner, Melissa [1 ]
Chow, Vincent [1 ]
Fanjiang, Gary [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.6361
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0645
引用
收藏
页码：1020 / 1020
页数：1
相关论文
共 49 条
  • [1] RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB
    Kaur, P.
    Chow, V.
    Zhang, N.
    Markus, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 714 - 714
  • [2] Immunological cross-reactivity of anti-drug antibodies to adalimumab and ABP 501
    Miller, J.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Krishnan, E.
    Kaliyaperumal, A.
    Zhang, N.
    Mytych, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S120 - S120
  • [3] Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
    Chow, V.
    Kaliyaperumal, A.
    Zhang, N.
    Miller, J.
    Mytych, D.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Krishnan, E.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S309 - S309
  • [4] DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 362 - 363
  • [5] Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modelling
    Doshi, S.
    Krishnan, E.
    Wang, H.
    Zhang, N.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S471 - S471
  • [6] Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapy
    Mytych, D.
    Miller, J.
    Manning, M. Starcevic
    Wala, I.
    Wang, H.
    Zhang, N.
    Krishnan, E.
    Kaliyaperumal, A.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S490 - S491
  • [7] Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
    Francois, Fabien
    Naimi, Loubna
    Roblin, Xavier
    Berger, Anne-Emmanuelle
    Paul, Stephane
    BMC IMMUNOLOGY, 2021, 22 (01)
  • [8] Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
    Fabien Francois
    Loubna Naimi
    Xavier Roblin
    Anne-Emmanuelle Berger
    Stephane Paul
    BMC Immunology, 22
  • [9] Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
    Manca Ogrič
    Polona Žigon
    David Drobne
    Borut Štabuc
    Snezna Sodin-Semrl
    Saša Čučnik
    Sonja Praprotnik
    Immunologic Research, 2018, 66 : 726 - 736
  • [10] ADALIMUMAB SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS
    Jyssum, I.
    Gehin, J. E.
    Kristianslund, E.
    Sexton, J.
    Worren, D.
    Hu, Y.
    Kvien, T. K.
    Haavardsholm, E. A.
    Bolstad, N.
    Syversen, S. W.
    Goll, G. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 421 - 422
12345